tradingkey.logo

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors at SNO Pediatric Conference

ReutersMay 29, 2025 1:10 PM

- Lantern Pharma Inc LTRN.O:

  • LANTERN PHARMA'S LP-184 SHOWS PROMISING IN VIVO ACTIVITY IN ATYPICAL TERATOID RHABDOID TUMORS (ATRT) AT SNO PEDIATRIC CONFERENCE, FURTHER VALIDATING RARE PEDIATRIC DISEASE DESIGNATION AND PATHWAY TO CLINICAL TRIALS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI